. 2024 Mar 21;11:1369136. doi: 10.3389/fmed.2024.1369136

Table 2.

Ongoing clinical trials of KRAS directed therapies in PDAC.

Clinical trial identifier	Agent	Phase	Mutation	Combination agent/comparator	Status
KRAS^G12C Inhibitors			KRAS ^G12C
NCT05263986	Adagrasib	I	AST		Active, not recruiting
NCT05634525	Adagrasib	I	PDAC		Recruiting
NCT05178888-KRYSTAL-16	Adagrasib	I	AST	w/palbociclib	Active, not recruiting
NCT05848843	Adagrasib	I	GI/NSCLC	w/durvalumab	Not yet recruiting
NCT06039384	Adagrasib	I	AST	w/INCB099280	Recruiting
NCT06117371	BEBT-607	I	AST		Recruiting
NCT04973163	BI-1823911	I	AST	w/BI 1701963, midazolam	Active, not recruiting
NCT05315180	BPI-421286	I	AST		Recruiting
NCT05410145	D3S-001	I	AST		Recruiting
NCT04449874	Divarasib	I	AST	w/atezolizumab, cetuximab, bevacizumab, erlotinib, GDC-1971, inavolisib	Recruiting
NCT05768321	GEC255	I	AST		Recruiting
NCT05485974	HBI-2438	I	AST		Recruiting
NCT04956640-LOXO-RAS-20001	Ly3537982	I	AST	w/abemeciclib, erlotinib, pembrolizumab, temuterkib, LY3295668, cetuximab, TNO155	Recruiting
NCT05067283	MK-1084	I	AST	w/pembrolizumab	Recruiting
NCT05462717	RMC-6291	I	AST		Recruiting
NCT06006793	SY-5933	I	AST		Recruiting
NCT06130254	Adagrasib	Ib	AST	w/olaparib	Not yet recruiting
NCT06128551	RMC-6291	Ib	AST	w/RMC-6236	Not yet recruiting
NCT03785249-KRYSTAL-1	Adagrasib	I/II	AST	w/cetuximab, pembrolizumab, afatinib	Recruiting
NCT04585035	Garsorasib	I/II	AST		Recruiting
NCT05379946	Garsorasib	I/II	AST	w/IN10018	Enrolling by invitation
NCT05005234	IBI351	I/II	AST		Recruiting
NCT05367778	HS-10370	I/II	AST		Recruiting
NCT05009329	Glecirasib	I/II	AST		Recruiting
NCT05002270	Glecirasib	I/II	AST	w/cetuximab	Recruiting
NCT04699188-KontRASt-01	JDQ443	I/II	AST	w/TNO155, tislelizumab	Recruiting
NCT05358249-KontRASt-03	JDQ443	I/II	AST	w/trametinib, ribociclib, cetuximab	Recruiting
NCT03600883-CodeBreaK100	Sotorasib	I/II	AST	w/anti PD-1/L1	Active, not recruiting
NCT04185883-CodeBreaK101	Sotorasib	I/II	AST	w/AMG404, trametinib, RMC-4630, afatinib, pembrolizumab, panitumumab, atezolizumab, everolimus, palbociclib, bevacizumab, TNO155, FOLFIRI, carboplatin, pemetrexed, docetaxel	Recruiting
NCT04892017	Sotorasib	I/II	AST	w/DCC-3116	Recruiting
NCT05173805	YL-15293	I/II	AST		Enrolling by invitation
NCT06008288	Glecirasib	II	PDAC		Not yet recruiting
NCT05993455	Sotorasib	II	AST	w/panitumumab	Active, not recruiting
NCT05638295-ComboMATCH	Sotorasib	II	AST	w/panitumumab	Not yet recruiting
KRAS^G12D Inhibitors			KRAS ^G12D
NCT05533463	HRS-4642	I	AST		Recruiting
NCT06040541	RMC-9805	I/Ib	AST		Recruiting
NCT05737706	MRTX1133	I/II	AST		Recruiting
KRAS^Multi Inhibitors			KRAS ^G12
NCT05379985	RMC-6236	I	AST		Recruiting
NCT04678648	RSC-1255	I	AST		Recruiting
			KRAS ^ANY
NCT06078800	YL-17231	II	AST		Recruiting
NCT06096974	YL-17231	I	AST		Not yet recruiting
SOS1 Inhibitors			KRAS ^ANY
NCT04111458	BI-1701963	I	AST	w/trametinib	Active, not recruiting
NCT04973163	BI-1701963	I	AST	w/BI-1823911	Active, not recruiting
NCT05578092	MRTX0902	I/II	AST	w/adagrasib	Recruiting
SHP2 Inhibitors			KRAS ^G12C
NCT05480865-ARGONAUT	BBP-398	I	AST	w/sotorasib	Recruiting
NCT05010694	GH35	I	AST		Recruiting
NCT05163028	HBI-2376	I	AST		Recruiting
NCT04916236-SHERPA	RMC-4630	I	CRC/NSCLC/PDAC	w/LY3214996	Recruiting
NCT06024174	BMS-986466	I/II	AST	w/adagrasib, cetuximab	Recruiting
NCT05288205	JAB-3312	I/II	AST	w/glecirasib	Recruiting
NCT04418661	RMC-4630	I/II	AST	w/pembrolizumab. Adagrasib	Active, not recruiting
NCT04330664-KRYSTAL-2	TNO155	I/II	AST	w/adagrasib	Active, not recruiting
			MAPK alterations
NCT05853367	MK-0472	I	AST	w/pembrolizumab	Recruiting
NCT03634982	RMC-4630	I	AST		Active, not recruiting
			No mutation req.
NCT04800822	ARRY-558		AST	w/lorlatinib, binimetinib, encorafenib, cetuximab	Active, not recruiting
NCT04528836	BBP-398	I	AST		Recruiting
NCT05369312	BBP-442096	I	AST		Not yet recruiting
NCT05354843	ET0038	I	AST		Recruiting
NCT04670679-FLAGSHP-1	ERAS-601	I	AST	w/cetuximab	Active, not recruiting
NCT05378178	HS-10381	I	AST		Recruiting
NCT04045496	JAB-3312	I	AST		Recruiting
NCT05505877	BR-790	I/II	AST	w/tislelizumab	Recruiting
NCT04866134	ERAS-601	I/II	AST	w/ERAS-007	Active, not recruiting
NCT03565003	JAB-3068	I	AST		Recruiting
NCT04720976	JAB-3312	I/II	AST	w/binimetinib, pembrolizumab, sotorasib, osimertinib	Recruiting
KRAS Degraders			KRAS ^G12D
NCT05382559	ASP3082	I	AST		Recruiting
Adoptive cell therapy
NCT05389514	Intermediate-size IND	I	AST KRAS^G12Vm	Chemo/immunotherapy	Available
NCT05933668	YK0901 TCR-T cell for KRAS G12V	I	AST		Not yet recruiting
NCT05438667	TCR-T cell therapy	I	PDAC		Recruiting
NCT06105021	Autologous CD8+/CD4+ TCR R cells	I/II	AST KRAS^G12Vm		Not yet recruiting
NCT04146298	Mutant KRAS G12V-specific TCR transduced T cell therapy	I/II	PDAC, KRAS^G12Vm	PD-1 inhibitor	Recruiting
NCT03745326	Peripheral blood lymphocytes with Murine KRASG12D TCR	I/II	PDAC/Gastric Ca/CRC	Cyclophosphamide, fludarabine, aldesleukin	Recruiting
NCT03190941	Peripheral blood lymphocytes transduced with Murine KRAS^G12V TCR in HLA-A*11:01	I/II	PDAC/Gastric Ca/CRC	Cyclophosphamide, fludarabine, aldesleukin	Recruiting
Vaccines
NCT04117087	Mutant KRAS-targeted long peptide vaccine	I	Resected MMR-p CRC, PDAC	Ipilimumab, nivolumab	Recruiting
NCT03592888	Dendritic cell vaccine	I	Resectable PDAC		Active, not recruiting
NCT04853017-AMPLIFY-201	ELI-002 immunotherapy	I	Adjuvant KRAS/NRAS PDAC/ST with MRD		Active, not recruiting
NCT05013216	Mutant KRAS-targeted long peptide vaccine	I	High risk of PDAC		Recruiting
NCT05631899	EphA1-targeting CAR-dendritic cell vaccine	I	AST, EphA2 overexpression	Anti-PD1 antibody	Recruiting
NCT05846516-KISIMA-02	ATP1450/ATP152	I	KRASm PDAC	VSV-GP154, ezabenlimab	Recruiting
NCT05726864-AMPLIFY7P	ELI-002-7P	I/II	Adjuvant AST		Recruiting
NCT05638698-TESLA	TG01	II	Resected PDAC w/ctDNA+	QS-21, balstilimab	Recruiting
NCT06015724	Anti-CD38 antibody with KRAS vaccine	II	PDAC/NSCLC	Anti-PD1 antibody	Recruiting
KRAS siRNAs
NCT03608631	Mesenchymal stromal cell-derived exosomes with KRAS G12D siRNA	I	Advanced PDAC KRAS ^G12Dm		Active, not recruiting